Safeguarding Cannabis for Medical Use: Clinical Risks, Regulatory Gaps, and the Path Toward Equitable Standards

Cannabis has moved into mainstream clinical use, yet the systems that should guarantee patient safety still lag. Oversight in the United States remains fragmented across states, with inconsistent thresholds, variable testing panels, and enforcement that often follows rather than prevents harm. Microbial contamination persists in regulated markets. Pathogenic Aspergillus has been detected in products that passed culture-based screens. Case reports in immunocompromised patients underscore real clinical consequences. Chemical contaminants, pesticides, heavy metals, and solvents, add cumulative risk and plausibly affect drug metabolism. State reforms have tried to tighten controls. Massachusetts required single-laboratory testing and digital certificate uploads. Those changes limited obvious lab shopping but left a fundamental flaw in place: cultivators and manufacturers still choose the samples. When sampling is compromised, even excellent laboratory work cannot protect patients. The 2025 suspension of Assured Testing Laboratories, along with recalls and lab actions in other states, shows the system's weakest points. International models demonstrate better paths. Canada uses pathogen-specific assays and broad pesticide panels, with high compliance. The European Medicines Agency has drafted pharmacopoeial standards for cannabis flos. Germany and Israel regulate cannabis as a medical product and link quality to reimbursement and distribution. My position is that U.S. policy should move to pathogen-specific molecular testing, harmonized chemical limits, and independent, regulator-controlled sampling. Equity protections are essential so safe products are accessible, not exclusive. Patients deserve cannabis regulated with the seriousness we expect for any therapeutic agent.